Converting to
REQUIP XL
- Appropriate patients may be switched directly from immediate-release ropinirole to REQUIP XL
- The initial switching dose of REQUIP XL should most closely match the total daily dose of immediate-release ropinirole
- Dosage may then be adjusted based on therapeutic response and tolerability
- In clinical trials, it was recommended that patients take REQUIP XL in the morning.
Important Safety Information About REQUIP XL
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.